StreetInsider.com News Articles

Form 8-K Autonomix Medical, Inc. For: Jul 13

Wed, 15 Jul 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260715/26774882.html

Form 8-K Autonomix Medical, Inc. For: Jul 13

Wed, 15 Jul 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260715/26774882.html

Autonomix Medical receives U.S. patent for overactive bladder platform

Wed, 15 Jul 2026 08:00:13 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,611,134, titled "Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder," expanding the company's neural sensing technology into urology.

The patented system is catheter-based and designed for minimally invasive access through the urethra to sense and treat overactive bladder at the bladder wall. The system is designed to map electrophysiological activity, including nerve activity, muscle activity, pressure responses, and tissue tone. The patent also covers targeted therapy delivery using radiofrequency ablation, thermal energy, ultrasonic energy, or localized therapeutic agents.

The patent

Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform

Wed, 15 Jul 2026 08:00:00 -0400

Newly Issued Patent Expands Company's Neural Sensing Technology Platform into Large Urology Market Affecting Approximately 37 Million Americans

THE WOODLANDS, TX, July 15, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 12,611,134, titled “Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder.”

The patent expands Autonomix's proprietary neural sensing and therapeutic technology into urology covering a new platform for the

Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform

Wed, 15 Jul 2026 08:00:00 -0400

Newly Issued Patent Expands Company's Neural Sensing Technology Platform into Large Urology Market Affecting Approximately 37 Million Americans

The patent expands Autonomix's proprietary neural sensing and therapeutic technology into urology covering a new platform for the

Autonomix Medical raises $2.6M via warrant inducement agreement

Tue, 14 Jul 2026 05:50:36 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) announced a warrant inducement agreement with an investor for the exercise of outstanding warrants originally issued on Nov. 19, 2025, according to a press release.

The investor agreed to exercise warrants to purchase 428,731 shares of common stock at a reduced exercise price of $6.00 per share. Gross proceeds are expected to be approximately $2.6 million before financial advisory fees and offering expenses. The transaction is expected to close on or about July 15, 2026, subject to customary closing conditions.

In exchange for the immediate cash exercise of the existing warrants, Autonomix agreed to issue two new

Autonomix Medical raises $2.6M via warrant inducement agreement

Tue, 14 Jul 2026 05:50:36 -0400

In exchange for the immediate cash exercise of the existing warrants, Autonomix agreed to issue two new

Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

Mon, 13 Jul 2026 21:30:00 -0400

THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on November 19, 2025 (the “November 2025 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding November 2025 Warrants to purchase an aggregate of 428,731 shares of the Company’s common stock at the amended and reduced exercise

Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

Mon, 13 Jul 2026 21:30:00 -0400

Autonomix Medical receives Canadian patent for neural sensing technology

Mon, 13 Jul 2026 07:30:45 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) announced it has been granted Canadian Patent No. 3,158,197, titled "Endoscopic Sympathectomy Systems and Methods," bringing the company's global intellectual property portfolio to 112 issued or pending patent applications worldwide.

The patent covers systems and methods for identifying, monitoring, and modulating autonomic nerves using minimally invasive tools capable of sensing physiological and electrophysiological activity before, during, and after treatment. Covered technologies include real-time monitoring of electrophysiological activity, nerve sensing and mapping, closed-loop neuromodulation systems, and microelectrode-based surgical tools.

The patented systems are designed to target autonomic nerves associated with conditions including hypertension, chronic heart failure, chronic renal

Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant

Mon, 13 Jul 2026 07:30:00 -0400

IP portfolio reflects Autonomix’s neural sensing leadership in multi-billion-dollar denervation market

Technical highlights on newly issued patent include real-time nerve monitoring and diagnostic evaluation

THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has been granted Canadian Patent No. 3,158,197, titled "Endoscopic Sympathectomy Systems and Methods." The Company’s growing global intellectual property portfolio now includes 112 issued or pending patent applications worldwide with the newest patent further strengthening the Company’s intellectual

Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant

Mon, 13 Jul 2026 07:30:00 -0400

IP portfolio reflects Autonomix’s neural sensing leadership in multi-billion-dollar denervation market

Technical highlights on newly issued patent include real-time nerve monitoring and diagnostic evaluation

THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has been granted Canadian Patent No. 3,158,197, titled "Endoscopic Sympathectomy Systems and Methods." The Company’s growing global intellectual property portfolio now includes 112 issued or pending patent applications worldwide with the newest patent further strengthening the Company’s intellectual

Form 8-K Autonomix Medical, Inc. For: Jul 09

Fri, 10 Jul 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260710/26755469.html

Form 8-K Autonomix Medical, Inc. For: Jul 09

Fri, 10 Jul 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260710/26755469.html

Form 8-K Autonomix Medical, Inc. For: Jun 18

Wed, 24 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260624/26682052.html

Form 8-K Autonomix Medical, Inc. For: Jun 18

Wed, 24 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260624/26682052.html

Autonomix Medical reports preclinical renal nerve sensing results

Mon, 22 Jun 2026 08:03:18 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) announced the development of a standalone neural sensing platform, citing preclinical results showing the ability to detect renal neural activity and measure real-time changes following intervention.

According to a press release, preclinical studies induced changes in blood pressure and observed reproducible changes in recorded neural signals in real time. The company said additional studies are underway to further characterize the relationship between those signals and sympathetic nerve activity.

The standalone platform is built on the same core sensing technology as Autonomix's lead pancreatic cancer pain program, which remains the company's primary clinical priority. The company said the

Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change

Mon, 22 Jun 2026 08:00:00 -0400

Platform Expected to Target Expansion into Multi-Billion-Dollar Cardiovascular Market with Potential Class II Diagnostic Regulatory Path

Architecture Supports Future Expansion into Denervation, including Renal, Pulmonary, Cardiac, Splanchnic and Other Nerve-Targeted Applications, with Potential Compatibility Across Multiple Denervating Technologies

THE WOODLANDS, TX, June 22, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the development of a proprietary standalone neural sensing platform following preclinical results showing evidence of the ability to identify renal neural activity and detect real-time

Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change

Mon, 22 Jun 2026 08:00:00 -0400

Platform Expected to Target Expansion into Multi-Billion-Dollar Cardiovascular Market with Potential Class II Diagnostic Regulatory Path

Autonomix Medical announces 1-for-21 reverse stock split

Thu, 18 Jun 2026 16:30:09 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) announced a 1-for-21 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on June 24, 2026, according to a press release from the company.

The medical device company filed an amendment to its certificate of incorporation with the Delaware Secretary of State to execute the split. Shares will begin trading on the Nasdaq Capital Market on a post-split basis on June 24, 2026, under the existing ticker symbol "AMIX" with a new CUSIP number of 05330T304.

Every 21 shares of common stock outstanding before the split will be consolidated into one share, with

Autonomix Announces Reverse Stock Split

Thu, 18 Jun 2026 16:30:00 -0400

THE WOODLANDS, TX, June 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-21 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on June 24, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market

Autonomix Announces Reverse Stock Split

Thu, 18 Jun 2026 16:30:00 -0400

Form 10-K/A Autonomix Medical, Inc. For: Mar 31

Mon, 15 Jun 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260615/26648730.html

Form 10-K/A Autonomix Medical, Inc. For: Mar 31

Mon, 15 Jun 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260615/26648730.html

Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Global Scientific and Clinical Recognition of Platform Technology

Wed, 10 Jun 2026 09:05:00 -0400

Access the segment here

THE WOODLANDS, TX, June 10, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the release of its latest CEO Corner segment featuring President and Chief Executive Officer, Brad Hauser.

As part of the segment, Mr. Hauser highlights the Company’s growing scientific and clinical recognition as its differentiated nerve-sensing and transvascular denervation platform gains traction across leading global medical conferences. Mr. Hauser highlighted that since last